74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Sanofi SA
Suletud
SektorTervishoid
75.92 -0.45
Ülevaade
Aktsiahinna muutus
24h
Min
74.91
Max
76.08
Sissetulek | -794M 2B |
|---|---|
Müük | 11B 24B |
P/E Sektori keskmine | 20.211 66.845 |
Aktsiakasum | 1.53 |
Dividenditootlus | 5.01 |
Kasumimarginaal | 8.459 |
Töötajad | 74,846 |
EBITDA | -3B 1.3B |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +22.45% upside |
Dividenditootlus Sektori keskmine | 5.01% 2.25% |
|---|---|
Järgmine tulemuste avaldamine | 23. apr 2026 |
Turukapital | 1.6B 98B |
|---|---|
Eelmine avamishind | 76.37 |
Eelmine sulgemishind | 75.92 |
Uudiste sentiment
By Acuity
44%
56%
110 / 351 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Sanofi SA Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Sanofi SA Prognoos
Hinnasiht
By TipRanks
22.45% tõus
12 kuu keskmine prognoos
Keskmine 93.542 EUR 22.45%
Kõrge 105 EUR
Madal 80 EUR
Põhineb 12 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
110 / 351 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Sanofi SA
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Live chat